Key result
Network pharmacology identifies 5 key gut metabolites linked to heart failure targets.
This network pharmacology study provides a hypothesis-generating framework for future experimental research on intervening in heart failure via gut microbiota-derived metabolites.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for gut microbiota metabolites in heart failure; warrants experimental validation before any clinical consideration.
Background Heart failure (HF) is a prevalent terminal-stage cardiovascular disease worldwide. Recent years have seen growing research on the gut-heart axis, yet the role of gut microbiota-derived metabolites in HF pathogenesis remains insufficiently explored. Methods This network pharmacology study screened overlapping targets of heart failure and gut metabolites via gutMGene, GeneCards and OMIM databases, then carried out PPI, enrichment, M-S-M-T network construction, as well as drug-likeness and toxicity prediction of metabolites. Results We identified 47 candidate targets at the intersection of HF-related genes and gut metabolite-associated targets. PPI network analysis suggested that AKT1, TNF, TP53, IL6, and PPARG may represent key hub targets. Functional enrichment indicated potential associations with the NF-κB and PI3K-Akt signaling pathways. The M-S-M-T regulatory network results show that PPARG is the hub target with the most extensive connections. Drug-likeness and toxicity predictions suggested favorable in silico profiles for five metabolites, including 3-indolepropionic acid (IPA) and indole-3-lactic acid (ILA). Conclusion This network pharmacology study screened core genes, metabolites and pathways associated with the gut-heart axis in heart failure, providing hypothetical support for subsequent experimental research on intervening heart failure via gut microbiota-derived metabolites.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2026) studied Heart failure. Gut microbiota-derived metabolites was evaluated on Candidate targets and metabolites associated with the gut-heart axis in heart failure. Network pharmacology analysis identified 47 candidate targets and 5 key metabolites, including 3-indolepropionic acid and indole-3-lactic acid, potentially mediating the gut-heart axis in heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: